European Neuropsychopharmacology
November 7, 2025
Mikkel Højlund, Helin Y. Kafali, Begüm Kırmızı et al.
12 citations
Serotonergic psychedelics and 3,4-methylendioxtmethamphetamine (MDMA) are promising treatments for mental disorders with a continuously evolving evidence base. We searched Pubmed/Scopus/clinical trial registries up to 08july2025 for double-blind randomized controlled trials (RCTs) testing MDMA or serotonergic psychedelics in patients with mental disorders. Primary outcomes were change in...
Translational Psychiatry
October 31, 2025
Giacomo D’andrea, Stefania Chiappini, Laura Ciavoni et al.
3 citations
BACKGROUND: Over the past ten years, several psychedelic compounds, including tryptamines like lysergic acid diethylamide/LSD, psilocybin, ayahuasca, and dimethyltryptamine/DMT, have been tested in clinical trials for a range of psychiatric conditions, such as anxiety and depression. While these compounds are relatively available for treatment, ketamine and its S(+) enantiomer, esketamine, are...
The Canadian Journal of Psychiatry
October 28, 2025
Jennifer Swainson, Elisa Brietzke, Atul Khullar et al.
2 citations
There has been a renewed interest in the use of various psychedelic agents as potential therapies for multiple psychiatric conditions, including post-traumatic stress disorder (PTSD), major depressive disorder (MDD), generalized anxiety disorder (GAD), to name a few. This follows the recent accumulation of evidence for ketamine pharmacotherapy and a rapid proliferation of clinics/programs...
Therapeutic Advances in Psychopharmacology
October 16, 2025
Stanley Wong, Brett D. M. Jones, Mathura T. Thiyagarajah et al.
3 citations
Background: Results from contemporary clinical trials of serotonergic psychedelic therapies have led to an increasing focus on their potential clinical use across mental disorders. However, studies examining mechanisms of clinical response to psychedelic therapy in psychiatric populations are limited. This review aimed to synthesize evidence from studies examining biomarkers of clinical...
Cortex
October 1, 2025
Roger Koenig-Robert, Rebecca Keogh, Joel Pearson
3 citations
Psychedelic therapy is on the rise, as its legalisation is ongoing in multiple countries. Here, we write a note of warning regarding recent reports that people with aphantasia (a blind mind's eye) have acquired visual mental imagery after using psychedelics. While the prospect of gaining, or indeed increasing, visual mental imagery is appealing to many, strong mental imagery has been associated...
Journal of Personalized Medicine
September 28, 2025
Kerem Kemal Soylemez, Emma Marie de Boo, Aysil Susuzlu et al.
2 citations
Psychedelic compounds are gaining renewed attention across disciplines for their profound psychological and neurobiological effects. Emerging research highlights their efficacy in treating mood disorders, PTSD, and addiction by enhancing neuroplasticity and disrupting maladaptive cognitive patterns. From a psychological standpoint, psychedelics facilitate introspection, emotional processing,...
Brain Sciences
September 12, 2025
Krista Ulisse, Jehad Albitar, Jourdan Aromin et al.
5 citations
Addiction remains a persistent public health crisis, marked by poor treatment retention and limited pharmacotherapy options. Emerging treatments, such as psychedelic-assisted psychotherapy and neuromodulation, offer promising avenues for circuit-level interventions in behavioral addictions. This narrative review synthesizes the current landscape of psychedelic compounds and neuromodulation...
Scientific Reports
September 1, 2025
Oscar Soto-Angona, Óscar Andión, Pablo Sabucedo et al.
3 citations
Preliminary evidence suggests that ayahuasca may alleviate severe grief symptoms. This three-arm, sequentially allocated, open-label study examines the therapeutic changes associated with ayahuasca-assisted meaning reconstruction therapy (A-MR) compared to meaning reconstruction therapy alone (MR) and a no-treatment control (NT). A total of 84 adults experiencing severe grief within 12 months...
Postepy psychiatrii neurologii
August 25, 2025
Nikolaos Statharakos, Elisavet Papadopoulou, Aaron J. Alvares et al.
1 citation
Purpose: Psychedelic substances are attracting attention for their therapeutic potential in mental health disorders. Emerging research suggests that even negative psychedelic experiences, or "bad trips," may hold therapeutic potential when managed in controlled settings. This narrative review explores the nature of "bad trips", their contributing factors, and their integration into therapeutic...
Expert Opinion on Drug Metabolism & Toxicology
August 19, 2025
Alice Caulfield, Elliot Hampsey, Allan H. Young
1. Classical psychedelics are gaining attention as potential treatments for a range of neuropsychiatric conditions, including depression, anxiety, and addictions [1]. Psychedelics differ from tradi...